Personalized tumor neoantigen-based peptide vaccine

drug_type

RELEVANT_DRUG

intervention_type

Biological

drug_description

A patient-specific therapeutic cancer vaccine composed of mutated peptide epitopes derived from the patient’s tumor (selected by exome/RNA sequencing and HLA typing). Administered subcutaneously, the peptides are taken up by antigen-presenting cells and presented on HLA class I/II to prime and boost neoantigen-specific CD8+ cytotoxic and CD4+ helper T-cell responses for tumor-specific killing and immune memory.

nci_thesaurus_definition

NCI thesaurus definition not available.

drug_mesh_term

Cancer Vaccines

drug_category

PEPTIDE VACCINE

drug_class

Vaccine

drug_delivery_route

Subcutaneous

drug_mechanism_of_action

Patient-specific mutated peptide epitopes from the tumor are administered subcutaneously and taken up by antigen‑presenting cells. The peptides are presented on HLA class I and II to prime and expand neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, driving tumor-specific recognition and killing and establishing immunologic memory.

drug_name

Personalized tumor neoantigen-based peptide vaccine

nct_id_drug_ref

NCT06751966